Gaddiel Galarza-Munoz
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2019First federal award
$2.7MFederal grants as PI7 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
7 awards · $2.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 26, 2023 | NIH | STTR Phase II Development of a novel accurate therapy for multiple sclerosis | $404K | AUTOIMMUNITY BIOLOGIC SOLUTIONS, INC. |
| Aug 22, 2022 | NIH | STTR Phase II Development of a novel accurate therapy for multiple sclerosis | $1.0M | AUTOIMMUNITY BIOLOGIC SOLUTIONS, INC. |
| Aug 17, 2022 | NIH | SBIR Phase I Strategy for specific delivery of antisense oligonucleotides to T cells | $307K | AUTOIMMUNITY BIOLOGIC SOLUTIONS, INC. |
| Aug 25, 2021 | NIH | SBIR Phase I Development of antisense oligonucleotides that enhance sIL7R as novel cancer immunotherapy | $325K | AUTOIMMUNITY BIOLOGIC SOLUTIONS, INC. |
| May 5, 2020 | NIH | STTR Phase I Determination of optimal antisense oligonucleotide chemistry for efficient and safe splicing modulation in T cells | $284K | AUTOIMMUNITY BIOLOGIC SOLUTIONS, INC. |
| Apr 4, 2019 | NIH | SBIR Phase I Novel accurate therapy for Multiple Sclerosis: Optimization of antisense oligonucleotides delivery and functionality in primary T cells | $170K | AUTOIMMUNITY BIOLOGIC SOLUTIONS, INC. |
| Jan 22, 2019 | NIH | STTR Phase I Development of a novel accurate therapy for Multiple Sclerosis | $225K | AUTOIMMUNITY BIOLOGIC SOLUTIONS, INC. |
Peer ranks
Federal funding#702
Awards as PI#250
Patents#273
Companies
- AUTOIMMUNITY BIOLOGIC SOLUTIONS, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.